N-acetylcysteine may improve residual renal function in hemodialysis patients: A pilot study

Hemodialysis International

Volumn 16, Issue 4, 2012, Pages 512-516

  Feldman, Leonid ^a,c   Shani, Michal ^b,c   Sinuani, Inna ^a   Beberashvili, Ilia ^a   Weissgarten, Joshua ^b,c  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Hemodialysis; N acetylcysteine; Residual renal function

Indexed keywords

ACETYLCYSTEINE; CREATININE; UREA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PILOT STUDY; PREVALENCE; PROSPECTIVE STUDY; RESIDUAL RENAL FUNCTION; URINE VOLUME;

ACETYLCYSTEINE; AGED; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; PERITONEAL DIALYSIS; PILOT PROJECTS; RENAL DIALYSIS;

EID: 84867101218     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00702.x     Document Type: Article

References (22)

1. Bargman J, Thorpe K, Churchill D, for the CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol. 2001; 12:2158-2162.
2. Brener Z, Thijssen S, Kotanco P, etal. The impact of residual renal function on hospitalization and mortality in incident hemodialysis patients. Blood Purif. 2011; 31:243-251.
3. Shemin D, Bostom A, Laliberty P, Dworkin L. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001; 38:85-90.
4. Termorshuizen F, Dekker F, van Manen J, Korevaar J, Boeschoten E, Krediet R, for the NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004; 15:1061-1070.
5. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation. 2003; 107:992-995.
6. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343:180-184.
7. Heyman S, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetylcysteine ameliorates renal microcirculation: Studies in rats. Kidney Int. 2003; 63:634-641.
8. Efrati S, Berman S, Ilgiyeav I, Siman-Tov Y, Averbukh Z, Weissgarten J. Differential effects of N-acetylcysteine, theophylline or bicarbonate on contrast-induced rat renal vasoconstriction. Am J Nephrol. 2009; 29:181-191.
9. Feldman L, Shani M, Efrati S, etal. N-acetylcysteine improves residual renal function in peritoneal dialysis patients: A pilot study. Perit Dial Int. 2011; 31:545-550.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for hemodialysis adequacy: Update 2006. Am J Kidney Dis. 2006; 48(Suppl 1):S17-S23.
11. Fouque D, Vennegoor M, Wee P, etal. EBPG guideline on nutrition. Nephrol Dial Transplant. 2007; 22(Suppl 2):45-87.
12. Prescott L, Illingworth R, Critchey J, Stewart M, Adam R, Proudfoot A. Intravenous N-acetylcysteine: The treatment of choice for paracetamol poisoning. BMJ. 1979; 2:1097-1100.
13. Mittermayer F, Schaller G, Pleiner J, etal. Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilatation of resistance arteries in peritoneal dialysis patients. J Am Soc Nephrol. 2005; 16:1832-1838.
14. Thada M, Widodo, Pranawa W, Yogiantoro M, Tomino Y. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Clin Nephrol. 2008; 69:24-32.
15. Drager LF, Andarde L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Serugo AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: Decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004; 19:1803-1807.
16. Danilovic A, Lucon AM, Srougi M, etal. Protective effect of N-acetylcysteine on early outcomes of deceased renal transplantation. Transplant Proc. 2011; 43:1443-1449.
17. Locatelli F, Canaud B, Eckardt K, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant. 2003; 18:1272-1280.
18. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000; 342:154-160.
19. Boaz M, Smetana S, Weinstein T, etal. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): Randomized placebo-controlled trial. Lancet. 2000; 356:1213-1218.
20. Izzedine H, Guerin V, Launay-Vacher V, Bernard M, Deray G. Effect of N-acetylcysteine on serum creatinine level. Nephrol Dial Transplant. 2001; 16:1514-1515.
21. Hoffman U, Fischereder M, Kruger B, Drobnik W, Kramer B. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004; 15:407-410.
22. Rehman T, Fought J, Solomon R. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol. 2008; 3:1610-1614.